OBIO® is advancing Canada’s competitive edge in health technology innovation and commercialization


The Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health science companies  positioning Ontario as a leader in the international marketplace.  OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, patients and  government.



popular OBIO Reports and Publications

CAAP® is Building Companies


The OBIO Capital Access Advisory Program operates downstream from existing entrepreneurship programs and targets the critical issue of access to capital at a post-seed stage of venture financing. OBIO CAAP strengthens Ontario’s cadre of investable human health science companies, increasing high value deal flow.



How Do VCs Value Health Science Companies?

fROM valuation to deal structure

On June 25th, OBIO participants had a unique opportunity to hear from experienced investors and analysts about how VCs think about valuation and how valuation is translated into deal structure. Participants also learned about commonly-used valuation methods, characteristics of equity and debenture instruments, calculating exit payouts, etc. 

Engaging with the FDA


On June 14th, OBIO hosted Dr. Yuan Fang (VP Regulatory Affairs, Quality and Manufacturing; Focal Healthcare Inc.) who spoke about his perspective on the recent changes at the U.S. Food and Drug Administration (FDA). Dr. Yuan spent over 8 years at the FDA Center for Devices and Radiological Health (CDRH), reaching the position of acting Branch Chief. During his talk, Dr. Yuan highlighted six important considerations when dealing with the FDA.

OBIO® Leadership Event

launch of obio's 2018 industry report

On May 3rd, OBIO welcomed health science leaders, CEOs and the investment community to the 10th annual OBIO Leadership Event.

Hosted at SPiN, Toronto's ping pong social club, the Leadership Event also saw the launch of Use It or Lose It: Industry Solutions to Ontario's Commercialization Gap, OBIO's 2018 industry report.

Showcasing Ontario's High Potential Companies

Niagara Health Science Emerging Company Forum

On February 1st and 2nd, OBIO - in partnership with Accel-Rx - hosted the Niagara Health Science Emerging Company Forum in beautiful Niagara-on-the-Lake. The event brought CEOs and senior executives from high potential Canadian health science companies together with senior leadership from American investors and strategics for two days of panel presentations, executive roundtables, networking dinners, and the opportunity to enjoy some of Canada’s finest wines.

One Stop Early-Stage Deal Flow for Investors


Pre-CAAP helps boost investability for early-stage health science companies at the seed or later stage who are developing health science services or products. Pre-CAAP companies get strategic business advice through one-on-one mentoring, subject matter specific workshops, and dedicated support and access to market research databases. They are groomed to be investor-ready through coaching and pitch review.



Digital Health           Medical Device/           Therapeutics

Improving Access to Motivated Early-Career Talent


H2BB is a collaborative initiative between academia and industry, aimed at improving access to talent across Ontario’s health science sector. Examples of what H2BB candidates can do includes conducting market research, business development, marketing and sales support, assisting with financial models, investor targeting and follow-up, and/or grant writing.